StockData
Enliven Therapeutics, Inc. logo

Enliven Therapeutics, Inc. (ELVN) stock

ELVNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/30
$46.85−0.77 (-1.62%)

Close on Nov 17, 2026Market cap $3.43BP/E –Yield –

Enliven Therapeutics r&d expenses

Research and development expenses are spending on new products and technology.

Enliven Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $89.15M, up 0.9% year over year. For fiscal 2025 it was $85.86M, up 6.3% from the year before. The highest annual figure on record is $85.86M in fiscal 2025.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$85.86M+6.3%
FY2024Dec 31, 2024$80.78M+25.1%
FY2023Dec 31, 2023$64.57M+108.2%
FY2022Dec 31, 2022$31.02M-19.3%
FY2021Dec 31, 2021$38.44M+19.6%
FY2020Dec 31, 2020$32.15M+69.2%
FY2019Dec 31, 2019$19.01M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$29.00M+34.9%
Q1 FY2026Mar 31, 2026$20.69M-16.9%
Q4 FY2025Dec 31, 2025$21.25M+2.5%
Q3 FY2025Sep 30, 2025$18.23M-14.3%
Q2 FY2025Jun 30, 2025$21.49M+14.2%
Q1 FY2025Mar 31, 2025$24.90M+24.7%
Q4 FY2024Dec 31, 2024$20.72M+15.7%
Q3 FY2024Sep 30, 2024$21.26M+8.4%
Q2 FY2024Jun 30, 2024$18.83M+24.0%
Q1 FY2024Mar 31, 2024$19.97M+68.1%
Q4 FY2023Dec 31, 2023$17.91M+118.4%
Q3 FY2023Sep 30, 2023$19.61M+150.4%
Q2 FY2023Jun 30, 2023$15.18M+91.3%
Q1 FY2023Mar 31, 2023$11.88M+68.3%
Q4 FY2022Dec 31, 2022$8.20M-24.5%
Q3 FY2022Sep 30, 2022$7.83M-24.7%
Q2 FY2022Jun 30, 2022$7.94M-21.2%
Q1 FY2022Mar 31, 2022$7.06M-0.8%
Q4 FY2021Dec 31, 2021$10.86M+21.2%
Q3 FY2021Sep 30, 2021$10.40M+9.1%
Q2 FY2021Jun 30, 2021$10.07M+28.0%
Q1 FY2021Mar 31, 2021$7.12M+22.8%
Q4 FY2020Dec 31, 2020$8.96M+50.8%
Q3 FY2020Sep 30, 2020$9.53M+85.4%
Q2 FY2020Jun 30, 2020$7.87M+80.2%
Q1 FY2020Mar 31, 2020$5.79M+62.7%
Q4 FY2019Dec 31, 2019$5.94M–
Q3 FY2019Sep 30, 2019$5.14M–
Q2 FY2019Jun 30, 2019$4.37M–
Q1 FY2019Mar 31, 2019$3.56M–

More Enliven Therapeutics figures

See a number that looks wrong?